Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 31,346 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study participants Clear all

Conditions: Nonalcoholic Steatohepatitis
Interventions: SEL, FIR, CILO, Placebo to match FIR, Placebo to match CILO, Placebo to match SEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 81
States / cities: Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 62 more

Conditions: Metastatic Colorectal Cancer
Interventions: Encorafenib, Cetuximab, Pembrolizumab; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 6
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Miami Beach, Florida + 2 more

Conditions: Financial Hardship, Alzheimer's Disease (AD), Alzheimer's Disease and Related Dementia (ADRD)
Interventions: Not listed
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2,460 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Contraceptives, Oral
Interventions: Daily Text Messages; Other
Lead sponsor: Columbia University; Other
Eligibility: Up to 24 Years · Female only
Enrollment: 968 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Healthy
Interventions: LY3154207, Placebo, Modafinil; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Glendale, California

Conditions: Postherpetic Neuralgia
Interventions: ADL5747, Placebo, Pregabalin; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: West Palm Beach, Florida

Conditions: Uveal Melanoma
Interventions: Darovasertib, Crizotinib (Xalkori); Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 20
States / cities: Scottsdale, Arizona • Los Angeles, California • San Diego, California + 13 more

Conditions: Myositis
Interventions: PF-06823859, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 45
States / cities: Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 22 more

Conditions: Sleep Initiation and Maintenance Disorders, Pregnancy
Interventions: No Intervention; Other
Lead sponsor: Eisai Inc.; Industry
Eligibility: 16 Years to 49 Years · Female only
Enrollment: 861 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Nutley, New Jersey

Conditions: Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors
Interventions: RO7566802, Atezolizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 6
States / cities: Birmingham, Alabama • New Haven, Connecticut • New York, New York + 3 more

Conditions: Healthy
Interventions: Drospirenone/ethinylestradiol, AL-335, Odalasvir (ODV), Simeprevir (SMV); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Hypertension, Diabetes Mellitus
Interventions: Self-monitoring-nurse-primary care provider feedback loop; Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years to 80 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Generalized Myasthenia Gravis
Interventions: Rozanolixizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 30
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 23 more

Conditions: Fatigue
Interventions: Muscadine grape extract, Placebo, Quality of Life Assessment, Questionnaires, Participant Feedback; Dietary Supplement · Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 65 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Stress Disorders, Post-Traumatic
Interventions: Prolonged Exposure (PE), Treatment as usual group therapy (TUGT), Supportive counseling (SC); Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 67 Years · Female only
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Advanced Cancers
Interventions: Fentanyl Pectin Nasal Spray, Placebo Nasal Spray, Walk Test, Questionnaires, Mental Ability Tests; Drug · Other · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer
Interventions: IMPROVED intervention; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Motion Sickness
Interventions: Tradipitant; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 705 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Effect of Methadone on the Duration on Mechanical Ventilation
Interventions: Methadone group, Usual care; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Malignant Glioma
Interventions: surveys and cognitive tests; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Surgical/Procedure Mask Fit Testing, KN95 Mask Fit testing; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy Volunteer
Interventions: [14C]-BIIB091; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Colorectal Carcinoma
Interventions: Dolcanatide, Laboratory Biomarker Analysis, Placebo Administration, Questionnaire Administration; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: Franz Rischard, DO; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Tucson, Arizona

Search by objective public record fields.

Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

Development of Measures to Screen for Financial Hardship in Alzheimer's Disease and Dementia

Txt Now 2 Decrease Pregnancies L8r: A Study to Evaluate the Effect of Daily Text Message Reminders on Pill Continuation

A Study of LY3154207 on Sleep in Healthy Male Participants

Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia

Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

A Study to Assess the Pregnancy Outcome in Women Exposed to Dayvigo® During Pregnancy Compared to an Unexposed Control Population

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female Participants

CONtrolling Disease Using Inexpensive IT - Hypertension in Diabetes

A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

Muscadine Grape Extract to Improve Fatigue

Prolonged Exposure Therapy for Post Traumatic Stress Disorder Following Sexual Assault

Fentanyl Pectin Nasal Spray (FNPS) for Exercise-Induced Breakthrough Dyspnea

Electronic Symptom Monitoring Intervention for Hospitalized Patients With Cancer

Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness

Impact of Methadone on Prolonged Mechanical Ventilation in Patients on Continuous Treatment With Opioids

Prognostic Awareness and Patient-Physician Communication in Malignant Glioma

Craniofacial Dimensions as Determinants of the Fitted Performance of Common Face Masks (FACEFIT 2.0)

A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male Participants

Dolcanatide in Preventing Colorectal Cancer in Healthy Volunteers

Reverse Remodeling of the Pulmonary Vasculature: a Longitudinal, Investigational Study of the Effects of Sotatercept.